| Literature DB >> 33662423 |
Asal Jalal Abadi1, Ali Zarrabi2, Farid Hashemi3, Amirhossein Zabolian4, Masoud Najafi5, Maliheh Entezari1, Kiavash Hushmandi6, Amir Reza Aref7, Haroon Khan8, Pooyan Makvandi9, Saeed Ashrafizaveh10, Tahereh Farkhondeh11, Milad Ashrafizadeh12, Saeed Samarghandian13, Michael R Hamblin14.
Abstract
Gastric cancer (GC) is a leading cause of death worldwide. GC is the third-most common cause of cancer-related death after lung and colorectal cancer. It is also the fifth-most commonly diagnosed cancer. Accumulating evidence has revealed the role of signaling networks in GC progression. Identification of these molecular pathways can provide new insight into therapeutic approaches for GC. Several molecular factors involved in GC can play both onco-suppressor and oncogene roles. Sex-determining region Y (Sry)-box-containing (SOX) family members are transcription factors with a well-known role in cancer. SOX proteins can bind to DNA to regulate cellular pathways via a highly conserved domain known as high mobility group (HMG). In the present review, the roles of SOX proteins in the progression and/or inhibition of GC are discussed. The dual role of SOX proteins as tumor-promoting and tumor-suppressing factors is highlighted. SOX members can affect upstream mediators (microRNAs, long non-coding RNAs and NF-κB) and down-stream mediators (FAK, HIF-1α, CDX2 and PTEN) in GC. The possible role of anti-tumor compounds to target SOX pathway members in GC therapy is described. Moreover, SOX proteins may be used as diagnostic or prognostic biomarkers in GC.Entities:
Keywords: Cancer therapy; Gastric cancer; High mobility group domain; SOX family members
Year: 2021 PMID: 33662423 DOI: 10.1016/j.ijbiomac.2021.02.202
Source DB: PubMed Journal: Int J Biol Macromol ISSN: 0141-8130 Impact factor: 6.953